Inclusion of trans women in pre-exposure prophylaxis trials: a review

References

• Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., … Celum, C. (2012). Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. New England Journal of Medicine, 367, 399–410. doi:10.1056/NEJMoa1108524
   PubMed Web of Science ®Google Scholar
• Baeten, J. M., Haberer, J. E., Liu, A. Y., & Sista, N. (2013). Preexposure prophylaxis for HIV prevention: Where have we been and where are we going? Journal of Acquired Immune Deficiency Syndromes, 63(Suppl. 2), S122–S129. doi:10.1097/QAI.0b013e3182986f69
   PubMedGoogle Scholar
• Baral, S. D., Poteat, T., Stromdahl, S., Wirtz, A. L., Guadamuz, T. E., & Beyrer, C. (2013). Worldwide burden of HIV in transgender women: A systematic review and meta-analysis. The Lancet Infectious Diseases, 13, 214–222. doi:10.1016/S1473-3099(12)70315-8
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. (2011). Interim guidance: Pre-exposure prophylaxis for the prevention of HIV infection in men who have sex with men. Morbidity and Mortality Weekly Report, 60(3), 65–68.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. (2012). Interim guidance for clinicians considering the use of pre-exposure prophylaxis for the prevention of HIV infection in heterosexually active adults. Morbidity Mortality Weekly Report, 61, 586–589.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. (2013). Update to interim guidance for pre-exposure prophylaxis (PrEP) for the prevention of HIV infection: PrEP for injecting drug users. Morbidity Mortality Weekly Report, 62, 463–465.
   PubMed Web of Science ®Google Scholar
• Choopanya, K., Martin, M., Suntharasamai, P., Sangkum, U., Mock, P. A., Leethochawalit, M., … Vanichseni, S. (2013). Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet, 381, 2083–2090. doi:S0140-6736(13)61127-7
   PubMed Web of Science ®Google Scholar
• Coombs, A., McFarland, W., Ick, T., Fuqua, V., Buchbinder, S. P., & Fuchs, J. D. (2014). Long-chain peer referral to recruit black MSM and black transgender women for an HIV vaccine efficacy trial. Journal of Acquired Immune Deficiency Syndromes, 66(4), e94–e97. doi:10.1097/QAI.0000000000000197
   Google Scholar
• Duncan, D. T., Hatzenbuehler, M. L., & Johnson, R. M. (2014). Neighborhood-level LGBT hate crimes and current illicit drug use among sexual minority youth. Drug and Alcohol Dependence, 135, 65–70. doi:10.1016/j.drugalcdep.2013.11.001
   PubMed Web of Science ®Google Scholar
• Galea, J. T., Kinsler, J. J., Salazar, X., Lee, S. J., Giron, M., Sayles, J. N., … Cunningham, W. E. (2011). Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: Barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. International Journal of STD & AIDS, 22, 256–262. doi:10.1258/ijsa.2009.009255
   PubMed Web of Science ®Google Scholar
• Golub, S. A. (2014). Tensions between the epidemiology and psychology of HIV risk: Implications for pre-exposure prophylaxis. AIDS Behavior, 18, 1686–1693. doi:10.1007/s10461-014-0770-7
   PubMed Web of Science ®Google Scholar
• Golub, S. A., & Gamarel, K. E. (2013). The impact of anticipated HIV stigma on delays in HIV testing behaviors: Findings from a community-based sample of men who have sex with men and transgender women in New York City. AIDS Patient Care and STDs, 27, 621–627. doi:10.1089/apc.2013.0245
   PubMed Web of Science ®Google Scholar
• Golub, S. A., Gamarel, K. E., Rendina, H. J., Surace, A., & Lelutiu-Weinberger, C. L. (2013). From efficacy to effectiveness: Facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. AIDS Patient Care and STDs, 27, 248–254. doi:10.1089/apc.2012.0419
   PubMed Web of Science ®Google Scholar
• Gomez, G. B., Borquez, A., Caceres, C. F., Segura, E. R., Grant, R. M., Garnett, G. P., & Hallett, T. B. (2012). The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: A mathematical modelling study. PLoS Medicine, 9, e1001323. doi:10.1371/journal.pmed.1001323PMEDICINE-D-11-01724
   Google Scholar
• Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., … Glidden, D. V. (2010). Pre-exposure chemoprophylaxis for HIV prevention in men who have sex with men. New England Journal of Medicine, 363, 2587–2599. doi:10.1056/NEJMoa1011205
   PubMed Web of Science ®Google Scholar
• Herbst, J. H., Jacobs, E. D., Finlayson, T. J., McKleroy, V. S., Neumann, M. S., Crepaz, N., & HIV/AIDS Prevention Research Synthesis Team. (2008). Estimating HIV prevalence and risk behaviors of transgender persons in the United States: A systematic review. AIDS Behavior, 12(1), 1–17. doi:10.1007/s10461-007-9299-3
   PubMed Web of Science ®Google Scholar
• Hoffman, B. (2014). An overview of depression among transgender women. [Review]. Depression Research and Treatment, 2014, Article ID 394283. doi:10.1155/2014/394283
   PubMedGoogle Scholar
• Marcus, J. L., Glidden, D. V., Mayer, K. H., Liu, A. Y., Buchbinder, S. P., Amico, K. R., … Grant, R. M. (2013). No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV pre-exposure prophylaxis. PLoS One, 8, e81997. doi:10.1371/journal.pone.0081997
   PubMed Web of Science ®Google Scholar
• Melendez, R. M., Exner, T. A., Ehrhardt, A. A., Dodge, B., Remien, R. H., Rotheram-Borus, M. J., … Hong, D. (2006). Health and health care among male-to-female transgender persons who are HIV positive. American Journal of Public Health, 96, 1034–1037. doi:10.2105/AJPH.2004.042010
   PubMed Web of Science ®Google Scholar
• Microbicides Trials Network. (2011). MTN statement on decision to discontinue use of oral tenofovir tablets in VOICE, a major HIV prevention study in women. Retrieved from http://www.mtnstopshiv.org/node/3619
   Google Scholar
• Molina, J. M., Pintado, C., Gatey, C., Ponscarme, D., Charbonneau, P., Loze, B., … Delaugerre, C. (2013). Challenges and opportunities for oral pre-exposure prophylaxis in the prevention of HIV infection: Where are we in Europe? BMC Medicine, 11, 186. doi:10.1186/1741-7015-11-186
   PubMed Web of Science ®Google Scholar
• Olyslager, F., & Conway, F. (2007, September). On the calculation of the prevalence of transsexualism. Paper presented at WPATH 20th International Symposium, Chicago, IL
   Google Scholar
• Peterson, L., Taylor, D., Roddy, R., Belai, G., Phillips, P., Nanda, K., … Cates, W. (2007). Tenofovir disoproxil fumarate for prevention of HIV infection in women: A phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clinical Trials, 2(5), e27. doi:10.1371/journal.pctr.0020027
   PubMedGoogle Scholar
• San Francisco Department of Health. (2013). HIV/AIDS epidemiology annual Report: 2012. Retrieved from http://www.sfdph.org/dph/files/reports/RptsHIVAIDS/AnnualReport2012.pdf
   Google Scholar
• Santos, G. M., Wilson, E. C., Rapues, J., Macias, O., Packer, T., & Raymond, H. F. (2014). HIV treatment cascade among transgender women in a San Francisco respondent driven sampling study. Sexually Transmitted Infections, 90, 430–433. doi:10.1136/sextrans-2013-051342
   PubMed Web of Science ®Google Scholar
• Sevelius, J. M., Carrico, A., & Johnson, M. O. (2010). Antiretroviral therapy adherence among transgender women living with HIV. The Journal of the Association of Nurses in AIDS Care, 21, 256–264. doi:10.1016/j.jana.2010.01.005
   Web of Science ®Google Scholar
• Sevelius, J. M., Patouhas, E., Keatley, J. G., & Johnson, M. O. (2014). Barriers and facilitators to engagement and retention in care among transgender women living with human immunodeficiency virus. Annals of Behavioral Medicine, 47(1), 5–16. doi:10.1007/s12160-013-9565-8
   PubMed Web of Science ®Google Scholar
• Sevelius, J. M., Saberi, P., & Johnson, M. O. (2014). Correlates of antiretroviral adherence and viral load among transgender women living with HIV. AIDS Care, 26, 976–982. doi:10.1080/09540121.2014.896451
   PubMed Web of Science ®Google Scholar
• Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., … Brooks, J. T. (2012). Antiretroviral pre-exposure prophylaxis for heterosexual HIV transmission in Botswana. The New England Journal of Medicine, 367, 423–434. doi:10.1056/NEJMoa1110711
   Web of Science ®Google Scholar
• Van Damme, L., Corneli, A., Ahmed, K., Agot, K., Lombaard, J., Kapiga, S., … Taylor, D. (2012). Pre-exposure prophylaxis for HIV infection among African women. The New England Journal of Medicine, 367, 411–422. doi:10.1056/NEJMoa1202614
   PubMed Web of Science ®Google Scholar
• van der Straten, A., Van Damme, L., Haberer, J. E., & Bangsberg, D. R. (2012). Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS, 26(7), F13–19. doi:10.1097/QAD.0b013e3283522272
   PubMed Web of Science ®Google Scholar
• World Health Organization. (2012). Guidance on Pre-Exposure Oral Prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: Recommendations for use in the context of demonstration projects. Retrieved from WHO website: http://www.who.int/hiv/pub/guidance_prep/en/
   Google Scholar
• Yang, D., Chariyalertsak, C., Wongthanee, A., Kawichai, S., Yotruean, K., Saokhieo, P., … Chariyalertsak, S. (2013). Acceptability of pre-exposure prophylaxis among men who have sex with men and transgender women in Northern Thailand. PLoS One, 8(10), e76650. doi:10.1371/journal.pone.0076650
   PubMed Web of Science ®Google Scholar